Detalhe da pesquisa
1.
Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.
Hepatology
; 78(6): 1755-1762, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37254559
2.
Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma.
Oncologist
; 27(11): e908-e911, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36103364
3.
Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150.
Gastroenterology
; 165(1): 286-288.e4, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36894034
4.
EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma.
Gastroenterology
; 164(6): 1006-1008.e3, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36708791
5.
Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma.
Cancer Res Commun
; 3(9): 1912-1916, 2023 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37772995
6.
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.
Cancer Res Commun
; 3(7): 1312-1317, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37484200
7.
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.
JHEP Rep
; 5(1): 100620, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36578451
8.
Effect of Radiation Treatment at a High-Volume Center on Outcomes in Intermediate-Risk Prostate Cancer: An Analysis of the National Cancer Database.
Urology
; 165: 242-249, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35182584
9.
Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
Nat Commun
; 13(1): 7477, 2022 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36463294
10.
Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center.
Cancer Med
; 9(18): 6658-6666, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32750219
11.
Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.
JCO Precis Oncol
; 7: e2200340, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36634295
12.
Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
Nat Commun
; 14(1): 7621, 2023 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37993437